Introduction {#S9}
============

Adverse fetal nutritional exposures may have persistent consequences for kidney health in later life. Specifically, suboptimal nutritional exposures during fetal life may affect nephrogenesis, leading to a reduced number of nephrons and smaller kidneys, which subsequently leads to glomerular hyperfiltration and sclerosis.[@R1], [@R2] The importance of early life nutrition for later kidney outcomes is illustrated by studies showing both associations of severe maternal undernutrition, preterm birth, and low birth weight with the risk of kidney disease in adulthood.[@R3], [@R4],[@R5] Not much is known about specific maternal nutritional exposures that persistently affect offspring kidney development.[@R4], [@R6] Folate is an essential B-vitamin, important for cell growth and replication and is together with vitamin B~12~, an important methyl donor in many reactions, including the production of thymidine for DNA synthesis, polyamine synthesis and biosynthesis of methionine from homocysteine.[@R7]--[@R9] Folate and vitamin B~12~ contribute to lowering homocysteine concentrations ([Figure 1](#F1){ref-type="fig"}).[@R10] Animal studies indicate that elevated homocysteine concentrations may lead to glomerular damage, and folic acid supplementation lowers creatinine concentration and urinary albumin excretion induced by hyperhomocysteinemia.[@R11] Also, studies in adults have shown associations of elevated homocysteine concentrations with an accelerated decline in kidney function.[@R12] Based on these findings, we hypothesized that lower folate and vitamin B~12~ concentrations and higher homocysteine concentrations during fetal life may affect nephrogenesis and lead to smaller kidneys with a lower kidney function.

Therefore, we examined, in a population-based prospective cohort study among 4,226 mothers and their children the associations of folate, vitamin B~12~ and homocysteine concentrations during first trimester of pregnancy and at birth with kidney outcomes in school-aged children.

Methods {#S10}
=======

Subjects {#S11}
--------

This study was embedded in the Generation R Study, an ongoing population-based prospective cohort study from fetal life onward in Rotterdam, the Netherlands.[@R13] The study was conducted according to the guidelines of the Helsinki Declaration and approved by the Medical Ethics Committee of Erasmus University Medical Center, Rotterdam (MEC-2007-413). Written informed consent was obtained from parents. At the age of 6 years, all participating children and their mothers were invited to participate in detailed measurements. Of 8,879 mother prenatally included in the study, 6,128 had measurements on folate, vitamin B~12~ or homocysteine concentrations. Of the 6,057 singleton live-born children from mothers with nutritional data available, 70% of them attended the follow-up visit at the age of 6 years. Children with successful information on at least one of the kidney measurements were included in the study (N = 4,226) ([Fig S1](#SD1){ref-type="supplementary-material"}).

Maternal and fetal folate, vitamin B~12~ and homocysteine concentrations {#S12}
------------------------------------------------------------------------

In early pregnancy (median gestational age 13.2 weeks (25th to 75th percentile 12.2, 14.8)) venous samples were drawn and stored at room temperature before being transported to the regional laboratory for processing. Cord blood samples were taken immediately after delivery (40.1 weeks of gestation, 25th to 75th percentiles 39.3--41.0 weeks).[@R13] To analyze folate, vitamin B~12~ and homocysteine concentrations, ethylenediaminetetraacetic acid plasma samples (folate, homocysteine) and serum samples (vitamin B~12~) were picked and transported to the Department of Clinical Chemistry at the Erasmus University Medical Centre, Rotterdam. After thawing, folate, homocysteine and vitamin B~12~ concentrations were analyzed using an immunoelectrochemoluminescence assay on the Architect System. These methods are described in detail elsewhere.[@R14] Folate concentrations were defined as: deficient when \< 7nmol/l or normal when ≥ 7 nmol/l.[@R15]

Folic acid supplement intake {#S13}
----------------------------

Information on folic acid supplement use (0.4--0.5 mg) and the initiation of supplementation was obtained by questionnaires at the enrolment of the study. We categorized folic acid supplement use into three groups: 1) periconceptional use; 2) start when pregnancy was known; 3) no use during pregnancy. Detailed information on folic acid supplement intake is described elsewhere.[@R16]

Childhood kidney outcomes {#S14}
-------------------------

As previously described, children's kidney outcomes were assessed at a median age of 6.0 years (25th to 75th percentiles 5.9, 6.3) in a dedicated research center in the Sophia Children's Hospital in Rotterdam.[@R17] Kidney volume was measured with ultrasound, using an ATL-Philips HDI 5000 instrument (Seattle, WA, USA), equipped with a 2.0-5.0MHz curved array transducer. We calculated kidney volume using the equation for a prolate ellipsoid.[@R18] Combined kidney volume was calculated by summing right and left kidney volume. Non-fasting blood samples were drawn by antecubital venipuncture. Creatinine concentrations were measured with enzymatic methods and cystatin C concentrations with a particle enhanced immunoturbidimetric assay (using Cobas 8000 analyzers, Roche, Almere, the Netherlands). Estimated glomerular filtration rate (eGFR) was calculated according to the revised Schwartz 2009 formula: eGFR~creat~ = 36.5 \* (height (cm) / serum creatinine (μmol/l)),[@R19] and Zappitelli's formula based on cystatin C concentrations: eGFR~cystC~ = 75.94 / \[CysC^1.17^\].[@R20] Urine creatinine (μmol/l) and urine albumin (μg/l) concentrations were determined with a Beckman Coulter AU analyzer, creatinine concentrations were measured with the Jaffe reaction. Microalbuminuria was defined as an albumin-creatinine ratio between 2.5 and 25 mg/mmol for boys and between 3.5 and 25 mg/mmol for girls.[@R21] Detailed information on kidney measures is described elsewhere.[@R17]

Covariates {#S15}
----------

We obtained information on maternal age, ethnicity, educational level, vitamins supplementation, smoking and alcohol usage during pregnancy using questionnaires.[@R13] We assessed maternal energy intake at enrollment using a validated semi-quantitative food frequency questionnaire.[@R22] Ethnicity and educational level were defined according to the classification of Statistics Netherlands.[@R23] Maternal pre-pregnancy height and weight were self-reported and pre-pregnancy body mass index (BMI) was calculated (kg/m^2^). We measured maternal blood pressure in early and late pregnancy by using the Omron 907 automated digital oscillometric spygmanometer.[@R24] Information on child's sex, birthweight and gestational age was available from medical records and hospital registries. We obtained information on breastfeeding from postnatal questionnaires.[@R17] At the age of 6 years, child height and weight were determined and BMI (kg/m^2^), and body surface area (BSA) (m^2^) were calculated.[@R25]

Statistical analysis {#S16}
--------------------

First, we performed a non-response analysis by comparing subject characteristics between children with and without follow-up kidney measurements by using T-tests, Chi-square tests and Mann-Whitney tests. Second, we used multivariable linear and logistic regression models to assess the associations of maternal first trimester and fetal cord blood folate, vitamin B~12~ and homocysteine concentrations with combined kidney volume, eGFR~creat~ and eGFR~cystC~, and risk of microalbuminuria in school-aged children. Folate, vitamin B~12~ and homocysteine concentrations were analysed continuously per standard deviation (SD)-increase to enable comparison between effect estimates. The regression models were first adjusted for child's sex, and age at kidney measurements (basic models), and subsequently also for maternal age, education, body mass index, blood pressure, vitamins supplementation, smoking, alcohol use, energy intake during pregnancy, and for child's birth weight, gestational age at birth, breastfeeding, and body surface area at the age of 6 years (confounder model). These covariates were included in the regression models based on previous literature or a change of \>10% in effect estimates. To explore if the observed associations of folate and vitamin B~12~ with kidney outcomes were independent of homocysteine concentrations, we additionally adjusted the confounder model for homocysteine concentrations (homocysteine model). In a separate model we additionally adjusted the kidney function measures for kidney volume (kidney size model). Third, we used the same models to assess the associations between maternal folic acid supplement intake and childhood kidney outcomes. These analyses, were performed among 3,291 mothers who had information on folic acid supplements. Whether the associations of folate or vitamin B~12~ or homocysteine and kidney outcomes differed by sex or birthweight we analyzed the interaction terms. Since the interaction terms were not significant we did not stratify our analyses. To prevent bias associated with missing data, we used multiple imputations (n=5) only for covariates with missing values on the basis of the correlation of missing variables with other participant characteristics, according to the Markov Chain Monte Carlo method.[@R26] Detailed information on multiple information procedure is given in [Supplementary Materials](#SD1){ref-type="supplementary-material"}. Subjects characteristics before and after imputation and the percentages of missing values are shown in [Table S1](#SD1){ref-type="supplementary-material"}. Statistical analyses were performed using the Statistical Package of Social Sciences version 21.0 (IBM SPSS Statistics for Windows, Armonk, NY: IBM Corp).

Results {#S17}
=======

Subject characteristics {#S18}
-----------------------

[Table 1](#T1){ref-type="table"} shows the characteristics of the study population stratified on folate concentrations. The values are based on the original data. [Table S2](#SD1){ref-type="supplementary-material"} shows folate, vitamin B~12~ and homocysteine concentrations per supplement group of folic acid use. The correlation coefficients of the investigated variables are given in [Table S3](#SD1){ref-type="supplementary-material"}. Maternal and cord blood folate, vitamin B~12~ and homocysteine concentrations correlation coefficients ranged from r= 0.34 to 0.46. Maternal folate and vitamin B~12~ concentrations were weakly negatively correlated with child height and weight, whereas homocysteine concentrations were weakly positively correlated with child height and weight ([Table S3](#SD1){ref-type="supplementary-material"}). Results from the non-response analyses are given in [Table S4](#SD1){ref-type="supplementary-material"}. Mothers whose children had kidney follow-up measurements had higher folate and vitamin B~12~, and lower homocysteine concentrations compared to mothers whose children did not have kidney follow-up measurements.

Maternal and fetal folate, vitamin B~12~ and homocysteine concentrations and childhood kidney outcomes {#S19}
------------------------------------------------------------------------------------------------------

[Table 2](#T2){ref-type="table"} shows that a 1-SD higher maternal folate concentration was associated with a 1.16 cm^3^ (95% confidence interval ((CI) 0.47, 1.85) larger childhood combined kidney volume. No other associations were observed of maternal folate concentrations with other kidney outcomes. A 1-SD higher maternal vitamin B~12~ concentration was associated with 1.00 ml/min/1.73m^2^ (95% CI 0.43, 1.57) higher childhood eGFR~cystC~. The effects estimates were similar when we adjusted for maternal homocysteine concentrations (homocysteine models) and childhood combined kidney volume (kidney size model). Similarly, a 1-SD higher maternal homocysteine concentration was associated with a -1.44 cm^3^ (95% CI -2.09, -0.79) smaller combined kidney volume and a -0.57 ml/min/1.73m^2^ (95% CI -1.13, -0.02) lower childhood eGFR~cystC~. The association of maternal homocysteine concentrations with childhood eGFR~cystC~ was largely explained by combined kidney volume. None of the exposures were associated with the risk of microalbuminuria. The results from basic models are given in [Table S5](#SD1){ref-type="supplementary-material"}.

[Table 3](#T3){ref-type="table"} shows that a 1-SD higher fetal cord blood homocysteine concentrations was associated with a 1.27 cm^3^ (95% CI 0.46, 2.08) larger childhood combined kidney volume and a -1.02 ml/min/1.73m^2^ (95% CI -1.76, -0.28) lower eGFR~cystC~,. The effect estimates on eGFR~cystC~ remained similar after additional adjustment for kidney size. Higher cord blood homocysteine concentrations was associated with lower eGFR~creat~ after additional adjustment for kidney size -0.91 ml/min/1.73m^2^ (95% CI -1.71, -0.12). No other associations were observed of cord blood folate and vitamin B~12~ concentrations with kidney outcomes. The results from basic models are given in [Table S6](#SD1){ref-type="supplementary-material"}.

[Table 4](#T4){ref-type="table"} shows that there was no association between folic acid supplement intake and kidney outcomes.

Discussion {#S20}
==========

Results from this population-based prospective cohort study suggest that maternal higher folate and lower homocysteine concentrations are associated with larger childhood combined kidney volume, whereas maternal higher vitamin B~12~ and lower homocysteine concentrations are associated with higher childhood eGFR~cystC~. Lower cord blood homocysteine concentrations were associated with smaller childhood combined kidney volume and higher eGFR.

Interpretation of main findings {#S21}
-------------------------------

Various lines of investigation suggest that an adverse fetal nutrition may have persistent consequences for kidney health in later life. As nephrogenesis continues until 36 weeks of gestation and largely ceases thereafter, adverse fetal nutritional exposures may have persistent impact on kidney function in later life.[@R1], [@R2] For this study, we specifically hypothesized that low folate and vitamin B~12~ concentrations and higher homocysteine concentrations during fetal life may affect nephrogenesis and lead to persistently smaller kidneys with a lower kidney function.

Not many studies have explored the effect of maternal folate concentrations or folic acid supplements during pregnancy on childhood kidney measures. Results from a trial follow-up study in Rural Bangladesh among 3,267 mother and their 4 to 5 year old children indicated no effect of early maternal multiple micronutrient supplementation or food supplementation with iron and folate on offspring's kidney volume.[@R27] A study exploring the effect of maternal folic acid supplements during pregnancy has suggested that folic acid supplements alone are a risk factor for congenital anomalies of kidney and urinary tract.[@R28] In our study only few children (n=6) had evidence of congenital kidney abnormalities. We did not observe any association of maternal folic acid supplements or cord blood folate concentrations with childhood kidney volume. However, our results suggest that higher maternal folate concentrations in early pregnancy are associated with a larger childhood combined kidney volume, independent of homocysteine concentrations. Specifically, folate concentrations in early pregnancy may affect child kidney volume. Folate concentrations are more directly related to the biological processes in the body than self-reported folic acid intake. Per se, they are a more precise measure of actual folate status, allowing for detection of potential subtle effects. This can explain why maternal folate concentrations were associated with childhood kidney volume, whereas folic acid supplementation was not. Furthermore, a continuous measure of folate concentration has statistically more power to detect differences compared to the categorical approach of folic acid supplementation. A study among young adults suggested that folic acid supplementation in subjects with low dietary content of folic acid was associated with decreased creatinine concentrations and subsequently higher eGFR.[@R29] Another study among 6 to 8 year old children in rural Nepal suggested that maternal folic acid supplementation reduced the risk of microalbuminuria.[@R30] Folate is important for homocysteine metabolism. Animal studies have shown that folic acid supplementation attenuates glomerular damage induced by hyperhomocysteinemia.[@R11] In our study, we did not observe any association of maternal or cord blood folate concentrations or folic acid supplementations with eGFR or microalbuminuria in 6 year old children. The differences in results may be explained by the different study populations. Vitamin B~12~ leads together with folate to lower homocysteine concentrations. We observed that higher vitamin B~12~ concentrations during fetal life were associated with a higher eGFR~cystC~. To the best of our knowledge, no previous studies have explored the relationship of vitamin B~12~ with kidney function measures in children. Epidemiological studies in renal failure patients suggested that parenteral vitamin B~12~ lowers homocysteine concentrations independent of serum vitamin B~12~ concentrations.[@R31] Previous studies have shown that after adjustment for homocysteine concentrations, higher vitamin B~12~ concentrations were associated with an increased risk of albuminuria. In individuals with high baseline homocysteine concentrations, increased vitamin B~12~ was associated with reduced kidney function.[@R32] Specifically, among hyperhomocysteinaemic patients vitamin-B supplementation modulated cystatin C concentrations.[@R33] In our study the observed associations of vitamin B~12~ with eGFR were independent of homocysteine concentrations. We did not observe any association of vitamin B~12~ concentrations with childhood microalbuminuria. Further research is needed to observe the effect of early life folate and vitamin B~12~ with kidney outcomes in later life.

Our results suggest that higher maternal homocysteine concentrations were associated with smaller combined kidney volume and lower eGFR. Nephrogenesis starts in early pregnancy, therefore high homocysteine concentrations since early pregnancy may influence on nephron formation. As we have previously reported, kidney size is positively correlated with eGFR.[@R34] We observed that an increased kidney volume explained the associations of maternal homocysteine concentrations with kidney function. Higher cord blood homocysteine concentrations were associated with larger combined kidney volume and lower eGFR. Our findings suggest time specific effects of homocysteine concentrations on kidney volume. It may be that a constant exposure to high homocysteine concentration induces kidney hypertrophy in originally smaller kidneys. To the best of our knowledge, there are no other studies in children to compare our findings. In line with our findings, in adults elevated homocysteine concentrations are associated with an accelerated decline in eGFR.[@R12], [@R35] Our findings are also supported by experimental studies in rats suggesting that elevated homocysteine concentrations can be an important pathogenic factor in glomerular damage.[@R11] Results from a study among 340 adults aged 50-75 years, suggested that increased homocysteine concentrations influence on the development of microalbuminuria.[@R36] In our study, we did not observe any association of homocysteine concentrations with the risk of microalbuminuria. It may be that the effects of impaired kidney growth on microalbuminuria may not be detectable during childhood, and become evident later in life. Altogether, these findings suggest time specific effects of homocysteine concentrations on kidney development. Previous studies using data from the same cohort have observed that low folate and high homocysteine but not vitamin B~12~ concentrations were associated with fetal growth restriction.[@R14] However, a previous study did not observe any association of maternal folate, vitamin B~12~ or homocysteine concentrations with blood pressure at the age of 6 years.[@R16]

Although we observed small effect sizes, our results may be important from a population-based perspective. In the Netherlands, the food supplies are not fortified with folic acid, but women are advised to use folic acid supplements (400 μg/day) prior to and up to the 10-12th week of pregnancy. Although the results presented in this study do not provide a basis to make causal statements, they support population-strategies to increase folate and vitamin B~12~ concentrations and subsequently lower homocysteine concentrations in pregnant women.

Potential mechanisms {#S22}
--------------------

From our observational study, it is not possible to establish the causality for the observed associations. However, some biological mechanisms may link maternal folate, vitamin B~12~ and homocysteine concentrations with childhood kidney outcomes. Both observational and experimental studies relate low folate and high homocysteine concentrations with endothelial dysfunction and altered vascular development.[@R12], [@R37]--[@R39] High homocysteine concentrations impair endothelial vasodilatation by inhibiting the generation of endothelial mediators and promoting adhesion between neutrophil and endothelial cells.[@R40] Homocysteine may also decrease levels of adenosine in plasma and interstitial tissue, and induce proliferation and apoptosis of glomerular mesangial cells, which leads directly to renal vascular injury.[@R41] Suboptimal vascular development and endothelial dysfunction could lead to hypertension in childhood which could be a predictor to chronic kidney diseases in later life.[@R2], [@R4] Also, maternal diet programs the embryonic kidney, altering cell turnover and gene expression at a time when nephrons and glomeruli have yet to form.[@R42] A beneficial effect of methyl donors, folate and vitamin B~12~ concentrations on childhood kidney outcomes support the hypothesis of epigenetic changes that program later kidney health.

Methodological considerations {#S23}
-----------------------------

To the best of our knowledge, this is the largest prospective population-based cohort study examining the associations of folate, vitamin B~12~ and homocysteine concentrations during fetal life with childhood kidney outcomes. We measured folate, vitamin B~12~ and homocysteine concentrations during early pregnancy and at birth, assessing critical periods of kidney development. Cord blood folate and vitamin B~12~ concentrations were higher compared to maternal concentrations. This is also reported previously in literature.[@R43] According to Dutch recommendations, we assume that after the 10-12th gestational week women did not take folic acid supplements. We obtained information on maternal folic acid supplementation using questionnaires. Mothers who did not take folic acid supplements in pregnancy had lower folate and higher homocysteine concentrations compared to mothers that started folic acid supplements periconceptional. Furthermore, these mothers had lower folate and vitamin B~12~ and higher homocysteine concentrations as compared to normal ranges of these concentrations during pregnancy.[@R44] Of the total group of singleton live-born children 70% had available information on kidney measurements. Selection bias in follow-up studies mainly arises from loss to follow-up than from non-response at baseline. Mothers of children without follow-up kidney measurements had lower folate and higher homocysteine concentrations, were younger, more with a non-European origin, smoked more frequently and used less alcohol during pregnancy, compared to mothers of children with available kidney measurements. Loss to follow-up would lead to selection bias if the associations of maternal first trimester micronutrient concentrations with childhood kidney outcomes would be different between those included and those not included in the final analyses. Because this is difficult to determine, selection bias cannot be excluded.

We performed detailed measurements on kidney outcomes. Kidney size was used as a measure of kidney development. Ultrasonography is a reliable method to measure kidney volume.[@R18] Kidney size is correlated with the number of glomeruli and can be used in epidemiologic studies as a measure of kidney development.[@R1] BSA is a well-known predictor of kidney volume. Replacement of BSA with BMI did not change the results. Similar effect estimates to combined kidney volume were observed when we explored Kidney volume/ BSA as an additional outcome.[@R45] To estimate GFR, we used the Schwartz formula based on creatinine concentrations and height, and also Zappitelli's formula based on cystatin C concentrations.[@R19], [@R20] In our analyses we observed small differences in effect estimates between eGFR~creat~ and eGFR~cystC~, with slightly stronger effect estimates for eGFR~cystC~. Random urine sample was used to evaluate the presence of microalbuminuria.[@R46] Our results apply to a relatively healthy sample of pregnant women and children. It may be that our findings could underestimate the true effect measures. Therefore, the generalizability of our results should be interpreted with caution in other populations. Finally, although we adjusted for a large number of potential maternal and childhood confounders, residual confounding, like child nutritional status, can still be present.

In conclusion, results from our prospective study, suggest that folate, vitamin B~12~ and homocysteine concentrations during fetal life affect offspring kidney measures. The effect sizes presented in the study are quite small, and the results could reflect confounding. Our findings should be considered as hypothesis generating and need further replication. Further follow-up studies are needed to examine the long term consequences for the risk of kidney diseases in later life.
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eGFR~creat~

:   estimated glomerular filtration rate based on creatinine concentrations

eGFR~cystC~

:   estimated glomerular filtration rate based on cystatin C concentrations

![Folate, vitamin B~12~ and homocysteine metabolism\
Schematic representation of homocysteine metabolism. Folate and vitamin B~12~ work closely together on homocysteine metabolism, handing off methyl groups to each other. TH-Folate is converted to 5,10-Methylene-TH-Folate which is further reduced to 5- Methyl-TH-Folate. With the demethylation of 5-Methyl-TH-Folate, the methyl group is donated into the methionine cycle. Vitamin B~12~ is involved directly in the transfer of the methyl group to homocysteine, through methionine synthase. Methionine synthase is a vitamin B~12~- dependent enzyme that catalyzes the formation of methionine from homocysteine The methionine cycle begins with homocysteine that accepts the methyl group from the folate pool through 5- Methyl-TH-Folate. Abbreviations: TH- Folate, Tetrahydro- folate.](emss-72479-f001){#F1}

###### Subject characteristics according to folate levels (N = 4,149)

                                                     Folate deficient (\< 7nmol/l) N = 277   Normal folate (≥7nmol/l) N = 3,872
  -------------------------------------------------- --------------------------------------- ------------------------------------
  **Maternal characteristics**                                                               
  Maternal age (y)                                   27.5 (5.6)                              30.6 (4.8)
  Pre-pregnancy body mass index(kg/m^2^)             23.7 (21.0, 27.0)                       22.6 (20.8, 25.2)
  *Missing, n (%)*                                   *60 (22)*                               *629 (16)*
  Gestational age at intake (wk)                     14.2 (12.6, 16.1)                       13.2 (12.1, 14.6)
  Early pregnancy systolic blood pressure (mmHg)     114 (12)                                116 (12)
  *Missing, n (%)*                                   *3 (1)*                                 *21 (0.5)*
  Early pregnancy diastolic blood pressure (mmHg)    67 (10)                                 68 (10)
  *Missing, n (%)*                                   *3 (1)*                                 *21 (0.5)*
  Late pregnancy systolic blood pressure (mmHg)      119 (12)                                119 (12)
  *Missing, n (%)*                                   *14 (5.1)*                              *120 (3.1)*
  Late pregnancy diastolic blood pressure (mmHg)     69 (10)                                 69 (9)
  *Missing, n (%)*                                   *14 (5.1)*                              *120 (3.1)*
  Education level, n (%)                                                                     
        -     No higher education                    204 (73.6)                              1,824 (47.1)
        -     Higher education                       44 (15.9)                               1,867 (48.2)
        -     *Missing, n (%)*                       *29 (10.5)*                             *181 (4.7)*
  Ethnicity, n (%)                                                                           
        -     European                               99 (35.7)                               2,555 (66.0)
        -     Non-European                           167 (60.3)                              1,264 (32.6)
        -     *Missing, n (%)*                       *11 (4)*                                *53 (1.4)*
  Smoking during pregnancy, n (%)                                                            
        -     Never & until pregnancy was known      154 (55.6)                              2,940 (75.9)
        -     Continued                              90 (32.5)                               545 (14.1)
        -     *Missing, n (%)*                       *33 (11.9)*                             *387 (10)*
  Alcohol during pregnancy, n (%)                                                            
        -     Never & until pregnancy was known      171 (61.7)                              1,939 (50.1)
        -     Continued                              59 (21.3)                               1,515 (39.1)
        -     *Missing, n (%)*                       *47 (17)*                               *418 (10.8)*
  Folic acid supplements use, n (%)                                                          
        -     No                                     166 (59.9)                              515 (13.3)
        -     Start 1st to 10 weeks                  23 (8.3)                                1,022 (26.4)
        -     Start periconceptional                 15 (5.4)                                1,492 (38.5)
        -     *Missing, n (%)*                       *73 (26.4)*                             *843 (21.8)*
  Maternal calories intake (kcal)                    2,010 (599)                             2,050 (549)
  *Missing, n (%)*                                   *76 (27.4)*                             *700 (18.1)*
  Vitamin supplements use, n (%)                                                             
        -     No                                     211 (76.2)                              2,193 (56.6)
        -     Yes                                    17 (6.1)                                1,114 (28.8)
        -     *Missing, n (%)*                       *49 (17.7)*                             *565 (14.6)*
  Folate plasma concentrations (nmol/l)              6.1 (5.4, 6.6)                          17.9 (11.6, 25.4)
  Vitamin B~12~ serum concentrations (pmol/l)        154.5 (115.8, 200.8)                    173.0 (131.0, 232.0)
  *Missing, n (%)*                                   *7 (2.5)*                               *235 (6.1)*
  Homocysteine plasma concentrations (μmol/l)        8.4 (7.1, 10.0)                         6.8 (6.0, 7.8)
  *Missing, n (%)*                                   *7 (2.5)*                               *62 (1.6)*
  **Infant characteristics**                                                                 
  Girls, n (%)                                       135 (48.7)                              1,941 (50.1)
  Gestational age at birth (wk)                      40.1 (39.3, 40.9)                       40.1 (39.3, 41.0)
  Birth weight (g)                                   3,309 (596)                             3,447 (548)
  *Missing, n (%)*                                   *-*                                     *4 (0.1)*
  Breastfeeding, n (%)                                                                       
        -     No                                     20 (7.2)                                231 (6.0)
        -     Yes                                    178 (64.3)                              2,940 (75.9)
        -     *Missing, n (%)*                       *79 (28.5)*                             *701 (18.1)*
  Cord blood folate concentrations (nmol/l)          16.6 (13.2, 21.2)                       21.1 (16.5, 27.3)
  Cord blood vitamin B~12~ concentrations (pmol/l)   267.5 (210.3, 379.8)                    302.0 (220.0, 422.0)
  Cord blood homocysteine concentrations (μmol/l)    9.8 (8.4, 12.3)                         9.3 (7.4, 10.6)
  **Child characteristics at 6y visit**                                                      
  Age (y)                                            6.1 (5.9, 6.5)                          6.0 (5.9, 6.2)
  Height (cm)                                        120.0 (6.9)                             119.3 (5.9)
  *Missing, n (%)*                                   *-*                                     *6 (0.2)*
  Weight (kg)                                        23.0 (20.8, 27.5)                       22.4 (20.4, 25.0)
  *Missing, n (%)*                                   *-*                                     *6 (0.2)*
  Body mass index (kg/m^2^)                          16.1 (15.3, 18.1)                       15.8 (15.0, 16.9)
  *Missing, n (%)*                                   *-*                                     *6 (0.2)*
  Body surface area (m^2^)                           0.9 (0.1)                               0.9 (0.1)
  *Missing, n (%)*                                   *-*                                     *6 (0.2)*
  Combined kidney volume (cm^3^)                     122.1 (28.6)                            120.0 (23.2)
  Creatinine (μmol/l)                                38.2 (5.2)                              37.3 (5.6)
  Cystatin C (mg/l)                                  783.1 (74.8)                            784.4 (81.8)
  eGFR~creat~ ( ml/min/1.73m^2^)                     117.1 (14.8)                            119.2 (16.3)
  eGFR~cystC~ ( ml/min/1.73m^2^)                     102.4 (13.5)                            102.5 (14.7)
  Microalbuminuria, n (%)                            24 (8.7)                                279 (7.2)

Values are frequency counts and percentages for categorical variables, means (SD) for continuous variables with a normal distribution, or medians (25th to 75th percentiles) for continuous variables with a skewed distribution. Values are based on the original data. Folate deficiency was defined as a folate concentration \< 7 nmol/l. Abbreviations: GFR~creat~ estimated glomerular filtration rate calculated based on creatinine blood levels: eGFR~cystC~ estimated glomerular filtration rate calculated based on cystatin C blood levels.

###### Associations of maternal folate, vitamin B~12~ and homocysteine concentrations during pregnancy with kidney outcomes at the age of 6 years (N = 4,226)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Difference in outcome measure (95% Confidence Interval)                                                                                                                                                    
  --------------------------------------------------------- ------------------------------------------------------------- ---------------------- ----------------------------------------------------------- --------------------
  **Folate**                                                                                                                                                                                                 

  Confounder Model                                          **1.16 (0.47, 1.85)[\*\*](#TFN2){ref-type="table-fn"}**\      0.01 (-0.65, 0.67)\    -0.03 (-0.63, 0.58)\                                        0.97 (0.85, 1.10)\
                                                            N = 3,818                                                     N = 2,792              N = 2,792                                                   N = 4,011

  Homocysteine Model                                        **1.02 (0.32, 1.72)[\*\*](#TFN2){ref-type="table-fn"}**\      -0.06 (-0.74, 0.61)\   -0.11 (-0.73, 0.51)\                                        0.96 (0.84, 1.10)\
                                                            N = 3,757                                                     N = 2,741              N = 2,741                                                   N = 3,944

  Kidney size Model                                                                                                       -0.24 (-0.90, 0.42)\   0.01 (-0.59, 0.61)\                                         0.95 (0.83, 1.09)\
                                                                                                                          N = 2,601              N = 2,601                                                   N = 3,686

  **Vitamin B~12~**                                                                                                                                                                                          

  Confounder Model                                          0.47 (-0.17, 1.11)\                                           0.20 (-0.43, 0.83)\    **1.00 (0.43, 1.57)[\*\*](#TFN2){ref-type="table-fn"}**\    1.06 (0.95, 1.19)\
                                                            N = 3,666                                                     N = 2,663              N = 2,663                                                   N = 3,849

  Homocysteine Model                                        0.20 (-0.45, 0.85)\                                           0.22 (-0.42, 0.85)\    **0.95 (0.36, 1.53)[\*\*](#TFN2){ref-type="table-fn"}**\    1.07 (0.96, 1.20)\
                                                            N = 3,563                                                     N = 2,579              N = 2,579                                                   N = 3,737

  Kidney size Model                                                                                                       0.09 (-0.53, 0.71)\    **0.96 (0.39, 1.52)[\*\*](#TFN2){ref-type="table-fn"}**\    1.08 (0.96, 1.21)\
                                                                                                                          N = 2,481              N = 2,482                                                   N = 3,538

  **Homocysteine**                                                                                                                                                                                           

  Confounder Model                                          **-1.44 (-2.09, -0.79)[\*\*](#TFN2){ref-type="table-fn"}**\   -0.55 (-1.15, 0.05)\   **-0.57 (-1.13, -0.02)[\*](#TFN2){ref-type="table-fn"}**\   1.08 (0.98, 1.20)\
                                                            N = 3,779                                                     N = 2,755              N = 2,755                                                   N = 3,969

  Kidney size Model                                                                                                       -0.35 (-0.97, 0.28)\   -0.52 (-1.10, 0.06)\                                        1.10 (0.99, 1.23)\
                                                                                                                          N=2,566                N = 2,556                                                   N = 3,649
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Values are linear and logistic regression coefficients (95% confidence interval). Confounder model is adjusted for maternal characteristics (age, body mass index before pregnancy, blood pressure in early pregnancy, ethnicity, education, vitamins supplementation, smoking, alcohol consumption , energy intake during pregnancy), and child characteristics (birthweight, gestational age, sex, breastfeeding, age and body surface area at 6 year visit). Homocysteine model is confounder model additionally adjusted for homocysteine concentrations during pregnancy. Kidney size model is confounder model additionally adjusted for child combined kidney volume. \*p \< 0.05, \*\*p\<0.01. Maternal folate, vitamin B~12~ and homocysteine concentrations were analyzed per 1 standard deviation in folate, vitamin B~12~ and homocysteine. Abbreviations: eGFR~creat~, estimated glomerular filtration rate based on creatinine concentrations; eGFR~cystC~, estimated glomerular filtration rate based on cystatin C concentrations.

###### Associations of cord blood folate, vitamin B~12~ and homocysteine concentrations with kidney outcomes at the age of 6 years (N = 2,674)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Difference in outcome measure (95% Confidence Interval)                                                                                                                                                                                        
  --------------------------------------------------------- ---------------------------------------------------------- ----------------------------------------------------------- ------------------------------------------------------------- --------------------
  **Folate**                                                                                                                                                                                                                                     

  Confounder Model                                          0.36 (-0.46, 1.18)\                                        0.41 (-0.36, 1.17)\                                         0.51 (-0.19, 1.22)\                                           0.97 (0.83, 1.13)\
                                                            N = 2,384                                                  N = 1,753                                                   N = 1,753                                                     N = 2,517

  Homocysteine Model                                        0.74 (-0.12, 1.59)\                                        0.30 (-0.50, 1.10)\                                         0.31 (-0.43, 1.06)\                                           1.00 (0.85, 1.17)\
                                                            N = 2,308                                                  N = 1,702                                                   N = 1,702                                                     N = 2,439

  Kidney size Model                                                                                                    0.37 (-0.39, 1.14)\                                         0.48(-0.24, 1.20)\                                            0.97 (0.82, 1.14)\
                                                                                                                       N = 1,625                                                   N = 1,625                                                     N = 2,306

  **Vitamin B~12~**                                                                                                                                                                                                                              

  Confounder Model                                          -0.47 (-1.27, 0.34)\                                       -0.52 (-1.28, 0.25)\                                        0.35 (-0.36, 1.05)\                                           0.99 (0.84, 1.15)\
                                                            N = 2,413                                                  N = 1,776                                                   N = 1,776                                                     N = 2,548

  Homocysteine Model                                        -0.05 (-0.90, 0.80)\                                       -0.76 (-1.56, 0.05)\                                        0.17 (-0.58, 0.92)\                                           1.00 (0.85, 1.17)\
                                                            N = 2,271                                                  N = 1,674                                                   N = 1,674                                                     N = 2,403

  Kidney size Model                                                                                                    -0.48 (-1.25, 0.29)\                                        0.42 (-0.30, 1.14)\                                           1.00 (0.85, 1.18)\
                                                                                                                       N = 1,645                                                   N = 1,645                                                     N = 2,335

  **Homocysteine**                                                                                                                                                                                                                               

  Confounder Model                                          **1.27 (0.46, 2.08)[\*\*](#TFN3){ref-type="table-fn"}**\   -0.74 (-1.53, 0.06)\                                        **-1.02 (-1.76, -0.28)[\*\*](#TFN3){ref-type="table-fn"}**\   1.09 (0.95, 1.26)\
                                                            N = 2,311                                                  N = 1,705                                                   N = 1,705                                                     N = 2,443

  Kidney size Model                                                                                                    **-0.91 (-1.71, -0.12)[\*](#TFN3){ref-type="table-fn"}**\   **-1.14 (-1.89, -0.39)[\*\*](#TFN3){ref-type="table-fn"}**\   1.09 (0.93, 1.27)\
                                                                                                                       N = 1,579                                                   N = 1,579                                                     N = 2,236
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Values are linear and logistic regression coefficients (95% confidence interval). Confounder model is adjusted for maternal characteristics (age, body mass index before pregnancy, blood pressure in late pregnancy, ethnicity, education, vitamins supplementation, smoking and alcohol consumption, energy intake during pregnancy), and child characteristics (birthweight, gestational age, sex, breastfeeding, age and body surface area at the age of 6year visit). Homocysteine model is confounder model additionally adjusted for homocysteine concentrations at birth. Kidney size model is confounder model additionally adjusted for child combined kidney volume. \*p \< 0.05, \*\*p\<0.01. Cord blood folate, vitamin B~12~ and homocysteine concentrations were analyzed per 1 standard deviation in folate, vitamin B~12~ and homocysteine. Abbreviations: eGFR~creat~, estimated glomerular filtration rate based on creatinine concentrations; eGFR~cystC~, estimated glomerular filtration rate based on cystatin C concentrations.

###### Associations of maternal folic acid supplements intake during pregnancy with kidney measurements at the age of 6 years (N = 3,291)

  Difference in outcome measure (95% Confidence Interval)                                                                    
  --------------------------------------------------------- --------------------- --------------------- -------------------- -------------------
  **Basic Model**                                                                                                            
  No (n = 696)                                              -1.63 (-3.78, 0.53)   0.18 (-1.58, 1.94)    0.50 (-1.14, 2.14)   0.77 (0.54, 1.10)
  Started when pregnancy was known (n = 1,065)              -0.89 (-2.74, 0.97)   -0.64 (-1.94, 0.66)   0.86 (-0.56, 2.28)   0.71 (0.52, 0.97)
  Started periconceptional (n = 1,530)                      *Reference*           *Reference*           *Reference*          *Reference*
  **Confounder Model**                                                                                                       
  No (n = 696)                                              -2.08 (-4.32, 0.15)   1.47 (-0.61, 3.55)    1.14 (-0.79, 3.08)   0.82 (0.54, 1.25)
  Started when pregnancy was known (n = 1,065)              -1.49 (-3.16, 0.18)   -0.27 (-1.83, 1.30)   1.17 (-0.29, 2.63)   0.75 (0.54, 1.03)
  Started periconceptional (n = 1,530)                      *Reference*           *Reference*           *Reference*          *Reference*

Values are linear and logistic regression coefficients (95% confidence interval). Basic model is adjusted for child's sex and age at 6 year visit. Confounder model is additionally adjusted for maternal characteristics (age, body mass index before pregnancy, blood pressure in early pregnancy, ethnicity, education, vitamin supplements, smoking, alcohol consumption, energy intake during pregnancy), and child characteristics (birthweight, gestational age, breastfeeding, age and body surface area at the age of 6y). \* p \< 0.05. Abbreviations: eGFR~creat~, estimated glomerular filtration rate based on creatinine concentrations; eGFR~cystC~, estimated glomerular filtration rate based on cystatin C concentrations.
